Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood.

Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, Furney S, Saleem M, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Coppola G, Geschwind D, Simmons A, Lovestone S, Dobson R, Hodges A; AddNeuroMed Consortium.

J Alzheimers Dis. 2012;30(3):685-710. doi: 10.3233/JAD-2012-111592.

PMID:
22466004
2.

Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.

Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, Groger J, Minnerup J, Wiendl H, Meuth SG, Duning T.

Neurobiol Aging. 2015 Jan;36(1):81-9. doi: 10.1016/j.neurobiolaging.2014.08.008. Epub 2014 Aug 23.

PMID:
25277040
3.

Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.

Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW.

Neurobiol Aging. 2014 Sep;35(9):1961-72. doi: 10.1016/j.neurobiolaging.2014.03.031. Epub 2014 Apr 2.

4.

Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer's Disease and Mild Cognitive Impairment Patients.

Delbarba A, Abate G, Prandelli C, Marziano M, Buizza L, Arce Varas N, Novelli A, Cuetos F, Martinez C, Lanni C, Memo M, Uberti D.

Oxid Med Cell Longev. 2016;2016:5923938. doi: 10.1155/2016/5923938. Epub 2016 Jan 6.

5.

Mitochondrial genes are altered in blood early in Alzheimer's disease.

Lunnon K, Keohane A, Pidsley R, Newhouse S, Riddoch-Contreras J, Thubron EB, Devall M, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Schalkwyk L, Dobson R, Malik AN, Powell J, Lovestone S, Hodges A; AddNeuroMed Consortium.

Neurobiol Aging. 2017 May;53:36-47. doi: 10.1016/j.neurobiolaging.2016.12.029. Epub 2017 Jan 7.

6.

Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood.

Proitsi P, Lee SH, Lunnon K, Keohane A, Powell J, Troakes C, Al-Sarraj S, Furney S, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Hodges A; AddNeuroMed Consortium.

Neurobiol Aging. 2014 Feb;35(2):279-90. doi: 10.1016/j.neurobiolaging.2013.08.002. Epub 2013 Sep 21.

PMID:
24064185
7.

Increased apoptosis in the platelets of patients with Alzheimer's disease and amnestic mild cognitive impairment.

Zhao S, Zhao J, Zhang T, Guo C.

Clin Neurol Neurosurg. 2016 Apr;143:46-50. doi: 10.1016/j.clineuro.2016.02.015. Epub 2016 Feb 11.

PMID:
26895209
8.

Buccal Cell Cytokeratin 14 Correlates with Multiple Blood Biomarkers of Alzheimer's Disease Risk.

Leifert WR, Nguyen T, Rembach A, Martins R, Rainey-Smith S, Masters CL, Ames D, Rowe CC, Macaulay SL, François M, Fenech MF; Australian Imaging, Biomarkers and Lifestyle Study Research Group.

J Alzheimers Dis. 2015;48(2):443-52. doi: 10.3233/JAD-150330.

PMID:
26402008
9.

Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease.

Silva DF, Santana I, Esteves AR, Baldeiras I, Arduino DM, Oliveira CR, Cardoso SM.

Curr Alzheimer Res. 2013 Feb;10(2):180-90.

PMID:
22746213
10.

Characteristic transformation of blood transcriptome in Alzheimer's disease.

Han G, Wang J, Zeng F, Feng X, Yu J, Cao HY, Yi X, Zhou H, Jin LW, Duan Y, Wang YJ, Lei H.

J Alzheimers Dis. 2013;35(2):373-86. doi: 10.3233/JAD-121963.

PMID:
23411692
11.

Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.

Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.

Neurobiol Aging. 2015 Feb;36(2):601-7. doi: 10.1016/j.neurobiolaging.2014.10.031. Epub 2014 Oct 31.

PMID:
25435336
12.

Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.

Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M, McEvoy M, Attia J, Schofield PW, Sachdev PS.

J Alzheimers Dis. 2015;43(4):1355-73. doi: 10.3233/JAD-141266.

PMID:
25159666
13.

Lymphocytic mitochondrial aconitase activity is reduced in Alzheimer's disease and mild cognitive impairment.

Mangialasche F, Baglioni M, Cecchetti R, Kivipelto M, Ruggiero C, Piobbico D, Kussmaul L, Monastero R, Brancorsini S, Mecocci P.

J Alzheimers Dis. 2015;44(2):649-60. doi: 10.3233/JAD-142052.

PMID:
25322927
14.

Chromosomal DNA damage measured using the cytokinesis-block micronucleus cytome assay is significantly associated with cognitive impairment in South Australians.

Lee SL, Thomas P, Hecker J, Faunt J, Fenech M.

Environ Mol Mutagen. 2015 Jan;56(1):32-40. doi: 10.1002/em.21890. Epub 2014 Aug 6.

PMID:
25099033
15.

Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.

Oh J, Lee HJ, Song JH, Park SI, Kim H.

Exp Gerontol. 2014 Dec;60:87-91. doi: 10.1016/j.exger.2014.10.004. Epub 2014 Oct 8.

PMID:
25304332
16.

Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.

Hakobyan S, Harding K, Aiyaz M, Hye A, Dobson R, Baird A, Liu B, Harris CL, Lovestone S, Morgan BP.

J Alzheimers Dis. 2016 Sep 6;54(2):707-16. doi: 10.3233/JAD-160420.

PMID:
27567854
17.

ADAM10 gene expression in the blood cells of Alzheimer's disease patients and mild cognitive impairment subjects.

Manzine PR, Marcello E, Borroni B, Kamphuis W, Hol E, Padovani A, Nascimento CC, de Godoy Bueno P, Assis Carvalho Vale F, Iost Pavarini SC, Di Luca M, Cominetti MR.

Biomarkers. 2015;20(3):196-201. doi: 10.3109/1354750X.2015.1062554. Epub 2015 Aug 4.

PMID:
26220620
18.

Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease.

Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, Henry M, Passmore AP, Young IS, Johnston JA.

Curr Alzheimer Res. 2013 Nov;10(9):973-8.

PMID:
24117116
19.

Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.

Forlenza OV, Diniz BS, Teixeira AL, Stella F, Gattaz W.

Rev Bras Psiquiatr. 2013 Jul-Sep;35(3):284-94. doi: 10.1590/1516-4446-2012-3505. Review.

20.

Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group.

Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20.

PMID:
24252258

Supplemental Content

Support Center